var data={"title":"Canakinumab: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Canakinumab: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388450?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=canakinumab-drug-information\" class=\"drug drug_general\">see &quot;Canakinumab: Drug information&quot;</a> and <a href=\"topic.htm?path=canakinumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Canakinumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874024\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ilaris;</li>\n      <li>Ilaris (150mg Delivered) [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14946785\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ilaris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13333947\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Interleukin-1 Receptor Antagonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334002\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=canakinumab-drug-information\" class=\"drug drug_general\">see &quot;Canakinumab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryopyrin-associated periodic syndromes (CAPS):</b> Patient syndromes included in trials were: Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystemic inflammatory disease (CINCA/NOMID), and familial cold urticaria (FCU); data has shown that pediatric patients require higher doses than adults (Kuemmerle-Deschner 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 40 kg: SubQ: Initial: 2 mg/kg/dose every 8 weeks; may increase to 3 mg/kg/dose if response inadequate</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: SubQ: 150 mg/dose every 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to &lt;4 years and weighing &ge;7.5 kg: SubQ: 4 mg/kg/dose every 8 weeks; if no response after 7 days, may repeat 4 mg/kg dose, if response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">7.5 kg to &lt;15 kg: SubQ: 4 mg/kg/dose every 8 weeks. If no response after 7 days, may administered a second 4 mg/kg/dose, if full treatment response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">15 kg to 40 kg: SubQ: 2 mg/kg/dose every 8 weeks. If response not satisfactory after 7 days, may repeat 2 mg/kg dose, if full treatment response achieved then may continue patient on intensified maintenance of 4 mg/kg/dose every 8 weeks. If after 7 days (ie, day 14) a satisfactory response still not achieved, may administer another 4 mg/kg dose, if full treatment response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017; Kuemmerle-Deschner 2011). Another dose-escalation regimen describes titration in 2 mg/kg/dose increments every 7 days up to a maximum dose of 8 mg/kg/dose (Ilaris prescribing information, Canada 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 kg: SubQ: 150 mg every 8 weeks. If response not satisfactory after 7 days, may repeat 150 mg/dose, if full treatment response achieved then may continue patient on intensified maintenance of 300 mg every 8 weeks. If after 7 days (ie, day 14) a satisfactory response still not achieved, may administer another 300 mg/dose, if full treatment response achieved then may continue patient on intensified maintenance of 600 mg every 8 weeks (Ilaris prescribing information, United Kingdom 2017; Kuemmerle-Deschner 2011). Another dose-escalation regimen describes titration in 150 mg increments every 7 days up to a maximum dose of 600 mg (Ilaris prescribing information, Canada 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Familial Mediterranean Fever (FMF): </b>Children &ge;2 years and Adolescents: <b>Note:</b> In trial, canakinumab was used as monotherapy and in combination with daily colchicine. Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.5 to 40 kg: SubQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: SubQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD): </b>Children &ge;2 years and Adolescents: Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.5 to 40 kg: SubQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: SubQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis; systemic:</b> Children &ge;2 years weighing at least 7.5 kg and Adolescents: SubQ: 4 mg/kg/dose every 4 weeks; maximum dose: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tumor necrosis factor receptor associated periodic syndrome (TRAPS):</b> Children &ge;2 years and Adolescents: Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.5 to 40 kg: SubQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: SubQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryopyrin-associated periodic syndromes (CAPS):</b> SubQ: 150 mg (&gt;40 kg) or 2 mg/kg (15 to 40 kg) every 8 weeks; in clinical trials, dosage adjustments up to 600 mg (&gt;40 kg) or 8 mg/kg (&le;40 kg) and/or increased dosing frequency were allowed for residual symptoms (Kuemmerle-Deschner 2011). For inadequate response, a dose titration schedule of 150 mg or 2 mg/kg every 7 days up to a maximum dose of 600 mg or 8 mg/kg (15 to 40 kg) has been recommended (Ilaris prescribing information, Canada 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Familial Mediterranean Fever (FMF), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): </b>SubQ: 150 mg (&gt;40 kg) or 2 mg/kg (&le;40 kg) every 4 weeks; may increase to 300 mg (&gt;40 kg) or 4 mg/kg (&le;40 kg) every 4 weeks if response is not adequate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;2 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;2 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9512584\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ilaris: 150 mg/mL (1 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ilaris (150mg Delivered): 180 mg (1 ea [DSC]) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7884596\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20403141\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM352352.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W92ivjwVDG4ZXa+dFfFcX3Q==&amp;TOPIC_ID=17066\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM352352.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334004\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Do not shake; administer subcutaneously at a concentration of 150 mg/mL by a health care provider; avoid sites with scar tissue</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883717\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. After reconstitution of powder, vials may be stored at room temperature for up to 1 hour or in a refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 4 hours. Protect from light prior to and after reconstitution. Discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13333958\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) (FDA approved in ages &ge;4 years and adults); treatment of active systemic juvenile idiopathic arthritis (SJIA) (FDA approved in ages &ge;2 years weighing at least 7.5 kg); treatment of tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF) (FDA approved in ages &ge;2 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883698\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum calcium (Lachmann 2009), weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, gastroenteritis, nausea, upper abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria (Lachmann 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased neutrophils (transient), decreased platelet count (mild and transient), decreased white blood cell count, eosinophilia (Lachmann 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin (Lachmann 2009), increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (non-neutralizing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (less common with serious infection), influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular and skeletal: Musculoskeletal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance (Lachmann 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, nasopharyngitis, pharyngitis, rhinitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883693\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to canakinumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active, severe infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883694\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: A decrease in WBC, neutrophils, and platelets was observed in clinical trials; some changes were transient and/or mild (eg, thrombocytopenia). One case of neutropenia (ANC &lt;1,500/mm<sup>3</sup>) was reported; monitor blood counts as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (excluding anaphylactic reactions) have been reported with use; symptoms may be similar to those that are disease related.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Caution should be exercised when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with latent or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued. Therapy should not be initiated in patients with active or chronic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrophage activation syndrome (MAS): MAS may develop in patients with SJIA and should be treated aggressively. Infection or worsening SJIA may be triggers for MAS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Use may impair defenses against malignancies; impact on the development and course of malignancies is not fully defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Avoid use in patients with active tuberculosis (TB). Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treat latent TB infections prior to initiating canakinumab therapy. During and following treatment, monitor for signs/symptoms of active TB.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: All patients should be brought up to date with all immunizations including pneumococcal and influenza vaccines before initiating therapy. Live vaccines should not be given concurrently; no data available on either the efficacy or on the risks concerning secondary transmission of infection by live vaccines in patients receiving therapy. Administration of inactivated (killed) vaccines while on therapy may not be effective.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26112890\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Influenza reported in 17% of patients during clinical trials. Vertigo has been reported exclusively in patients with MWS (9% to 14%); events appear self-resolving with continued therapy. Infection reported more frequently in children than adults (Kuemmerle-Deschner 2011) for both CAPS and JIA. Treatment for CAPS has been associated with higher incidence of reported adverse reactions including diarrhea (20%), nasopharyngitis (34%), and rhinitis (17%).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298949\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7899286\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17066&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interleukin-1 Receptor Antagonist: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883689\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Canakinumab is a recombinant IgG monoclonal antibody; IgG is known to cross the placenta in a linear fashion as pregnancy progresses; potential fetal exposure is likely to be greater during the second and third trimesters.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334005\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, C-reactive protein (CRP), serum amyloid A; LFTs at baseline; signs or symptoms of infection; latent TB screening (prior to initiating therapy), body weight. Eye examinations for patients with CAPS (Caorsi 2013) and symptoms of disease for patients with CAPS, SJIA, TRAPS, FMF, or HIDS/MKD (Arostegui 2015; Brik 2014; Caorsi 2013; Lachmann 2009; Ruperto 2012; Torene 2017) were also monitored in clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883719\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1beta) (no binding to IL-1 alpha  or IL-1 receptor antagonist [IL-1ra]) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates IL-1beta activation. Deficiency of cryopyrin results in excessive inflammation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7883721\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximum effect: Within 8 days CRP and serum amyloid normalization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Children: 0.097 L/kg (3.2 L in 33 kg); Adults: CAPS: 0.086 L/kg (6 L in 70 kg); FMF, HIDS/MKD, TRAPS: 0.09 L/kg (6.34 L in 70 kg).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Binds to serum IL-1 beta</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Subcutaneous: 66%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children &ge;4 years: 22.9 to 25.7 days; Adults: 26 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Children &ge;4 years: 2 to 7 days; Adults: ~7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Varies according to body weight:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &le;40 kg: SJIA: 0.11 L/day in 33 kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;40 kg and Adults: CAPS: 0.174 L/day in 70 kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children, Adolescents, and Adults: FMF, HIDS/MKD, TRAPS: 0.17 L/day in 70 kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322118\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ilaris Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $19,266.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707699\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ilaris (AE, AR, AT, BE, BR, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IL, JP, KR, KW, LT, LU, MT, NL, NO, NZ, PH, PL, PT, QA, SA, SE, SG, SI, SK, TR, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arostegui JI, Anton J, Calvo I, et al. Long-term efficacy and safety of canakinumab in active hyper-IgD syndrome (HIDS): results from an open-label study. <i>Pediatric Rheumatology</i>. 2015;13(supp 1):58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. <i>Arthritis Rheumatol</i>. 2014;66(11):3241-3243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/25049046/pubmed\" target=\"_blank\" id=\"25049046\">25049046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. <i>Arthritis Res Ther</i>. 2013;15(1):R33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/23442610/pubmed\" target=\"_blank\" id=\"23442610\">23442610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furst DE, Keystone EC, Braun J, et al, &quot;Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2010,&quot; <i>Ann Rheum Dis</i>, 2011, 70(Suppl 1)2-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/21339216/pubmed\" target=\"_blank\" id=\"21339216\">21339216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilaris (canakinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilaris powder for injection (canakinumab) [prescribing information]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilaris powder for injection (canakinumab) [prescribing information]. West Sussex, United Kingdom: Novartis Europharm Limited. February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al, &quot;Two-Year Results From an Open-Label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Across Different Severity Phenotypes,&quot; <i>Ann Rheum Dis</i>, 2011, Aug 21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/21859692/pubmed\" target=\"_blank\" id=\"21859692\">21859692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, &quot;Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome,&quot;<i> N Engl J Med</i>, 2009, 360(23):2416-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/19494217/pubmed\" target=\"_blank\" id=\"19494217\">19494217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NCT 00685373, &ldquo;Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease&rdquo;, Unpublished data. Available at <a href=\"http://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;amp;rank=1\" target=\"_blank\">http://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;rank=1</a>. Date Accessed: October 29, 2011</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Brunner H, Horneff G, et al, &ldquo;Efficacy and Safety of Canakinumab, a Longacting Fully Human Anti-Interleukin-1&szlig; Antibody, in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features: Results From a Phase III Study,&rdquo;<i> Pediatric Rheumatology</i>, 2011, 9(Suppl 1):021.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. <i>N Engl J Med</i>. 2012;367(25):2396-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/23252526/pubmed\" target=\"_blank\" id=\"23252526\">23252526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Quartier P, Wulffraat N, et al, &quot;A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features,&quot; <i>Arthritis Rheum</i>, 2012, 64(2):557-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/21953497[/pubmed\" target=\"_blank\" id=\"21953497[\">21953497[</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torene R, Nirmala N, Obici L, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. <i>Ann Rheum Dis</i>. 2017;76(1):303-309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/canakinumab-pediatric-drug-information/abstract-text/27474763/pubmed\" target=\"_blank\" id=\"27474763\">27474763</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17066 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7874024\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14946785\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F13333947\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13334002\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9512584\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F7884596\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F20403141\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13334004\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7883717\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13333958\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7883698\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7883693\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7883694\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26112890\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298949\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7899286\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7883689\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13334005\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7883719\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F7883721\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322118\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707699\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/17066|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=canakinumab-drug-information\" class=\"drug drug_general\">Canakinumab: Drug information</a></li><li><a href=\"topic.htm?path=canakinumab-patient-drug-information\" class=\"drug drug_patient\">Canakinumab: Patient drug information</a></li></ul></div></div>","javascript":null}